Ifosfamide metabolite chloroacetaldehyde causes fanconi syndrome in the perfused rat kidney

Toxicology and Applied Pharmacology

Volumn 129, Issue 1, 1994, Pages 170-175

  Zamlauski Tucker, Marianna J ^a,b,c   Morris, Marilyn E ^a,b,c   Springate, James E ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0027971523     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1994.1241     Document Type: Article

References (33)

1. Beauchamp, R. O., Andjelkovich, D. A., Kligerman, A. D., Morgan, K. T., and Heck, H. D. (1985). A critical review of the literature on acrolein toxicity. CRCCril. Rev. Toxicol. 14, 309-380.
2. Bekersky, I. (1983). Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab. Rev. 14, 931-960.
3. Boddy, A. V., and Idle, J. R. (1992). Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. J. Chromatogr. 575, 137-142.
4. Brodehl, J. (1992). The Fanconi syndrome. In Pediatric Kidney Disease (C. M. Edelmann, Ed.), pp. 1841-1871. Little, Brown and Co., Boston.
5. Burckhardt, G., and Ullrich, K. J. (1989). Organic anion transport across the contraluminal membrane-Dependence on sodium. Kidney Int. 36, 370-377.
6. Burk, C. D., Restaino, I., Kaplan, B. S., and Meadows, A. T. (1990). Ifosfa-mide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J. Pediatr. 117, 331-335.
7. Dechant, K. L., Brogden, R. N., Pilkington, T., and Faulds, D. (1991). Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42, 428-467.
8. Foiles, P. G., Miglietta, L. M., Nishikawa, A., Kusmierek, J. T., Singer, B., and Chung, F.-L. (1993). Development of monoclonal antibodies specific for l, N2-ethenodeoxyguanosine and N2, 3-ethenodeoxyguanosine and their use for quantitation of adducts in G12 cells exposed to chloroa-cetaldehyde. Carcinogenesis 14, 113-116.
9. Foreman, J., Raney, B., Ensign, L., Ortega, J., Ragab, A., Ruymann, F., Gehan, E., and Maurer, H. (1992). Renal toxicity in patients treated with ifosfamide on intergroup rhabdomyosarcoma study. J. Am. Soc. Nephrol. 3, 311.
10. Fuhr, J., Kacmarczyk, J., and Kruttgen, C. D. (1955). Eineeinfache colori-metirische methode zur inulin bestimmung fur nieren-clearance-unter-suchungen bei stoffwechse’-gelsunden und diabetekern. Pfflugers Arch. 267, 128-137.
11. Goren, M. P., Wright, R. K., Pratt, C. B., and Pell, F. E. (1986). Dechlor-oethylation of ifosfamide and neurotoxicity. Lancet 2, 1219-1220.
12. Goren, M. P. (1991). Determination of urinary 2-and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography. J. Chromatogr. 570, 351-359.
13. Horvath, J. J., Witmer, C. M., and Witz, G. (1992). Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat. Toxicol. Appl. Pharmacol. 117, 200-207.
14. Kaijser, G. P., Beijnen, J. H., Jeunink, E. L., Bult, A., Keizer, H. J., de Kraker, J., and Underberg, W. J. (1993). Determination of chloroacetal-dehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J. Chromatogr. 614, 253-259.
15. Kurowski, V., Cerny, T., Kupfer, A., and Wagner, T. (1991). Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J. Cancer Res. Clin. Oncol. 117, S148-S153.
16. Lin, J. H., and Levy, G. (1983). Renal clearance of inorganic sulfate in rats: Effect of acetaminophen-induced depletion of endogenous sulfate. J. Pharm. Sci. 72, 213-217.
17. Lind, M. J., Roberts, H. L., Thatcher, N„ and Idle, J. R. (1990). The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother. Pharmacol. 26, 105-111.
18. Maack, T. (1986). Renal clearance and isolated kidney perfusion techniques. Kidney Int. 30, 142-151.
19. Mohrmann, M., Pauli, A., Ritzer, M., Schonfeld, B., Seifert, B., and Bran-dis, M. (1992). Inhibition of sodium-dependent transport systems in LLC-PK, cells by metabolites of ifosfamide. Renal Physiol. Biochem. 15, 289-301.
20. Mohrmann, M., Pauli, A., Walkenhorst, H., Schonfeld, B., and Brandis, M. (1993). Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular ceils (LLC-PK) in culture. Renal Physiol. Biochem. 16, 285-298.
21. Mohrmann, M., Ansorge, S., Schmich, U., Schonfeld, B., and Brandis, M. (1994). Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pedialr. Nephrol. 8, 157-163.
22. Morris, M. E. and Levy, G. (1988). Assay of inorganic sulfate in biologic fluids by nonsuppressed (single-column) ion chromatography. Anal. Biochem. 172, 16-21.
23. Mujais, S. K. (1993). Maleic acid-induced proximal tubulopathy: Na: K pump inhibition. J. Am. Soc. Nephrol. 4, 142-147.
24. Murer, H., Manganel, M., and Roch-Ramel, F. (1992). Tubular transport of monocarboxylates, Krebs cycle intermediates and inorganic sulfate. In Handbook of Physiology. Section 8: Renal Physiology (E. E. Wind-hager, Ed.), pp. 2165-2188. Oxford Univ. Press. New York.
25. Parent, R. A., Caravello, H. E., Balmer, M. F., Shellenberger, T. E„ and Long, J. E. (1992a). One-year toxicity of orally administered acrolein to the beagle dog. J. Appl. Toxicol. 12, 131-139.
26. Parent, R. A., Caravello, H. E., and Long, J. E. (1992b). Two-year toxicity and carcinogenicity study of acrolein in rats. J. Appl. Toxicol. 12, 311-316.
27. Pearcey, R., Calvert, R., and Mehta, A. (1988). Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemother. Pharmacol. 22, 353-355.
28. Shore, R., Greenberg, M., Geary, D., and Koren, G. (1992). Iphospha-mide-induced nephrotoxicity in children. Pedialr. Nephrol. 6, 162-165.
29. Skinner, R., Sharkey, I. M., Pearson, A. D. J., and Craft, A. W. (1993). Ifosfamide, mesna and nephrotoxicity in children. J. Clin. Oncol. 11, 173-190.
30. Smith, H. W., Finkelstein, N., Aliminosa, L., Crawford, B., and Graber, M. (1945). The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J. Clin. Invest. 24, 388-404.
31. Suarez, A., McDowell, H., Niaudet, P., Comoy, E., and Flamant, F. (1991). Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors. J. Clin. Oncol. 9, 2177-2182.
32. Winckler, K., Obe, G., Madle, S., Kochler-Becker, U., Kocker, W., and Nau, H. (1987). Cyclophosphamide: Interstrain differences in the production of mutagenic metabolites by S9-fractions from liver and kidney in different mutagenicity test systems in vitro and in the teratogenic response in vivo between CBA and C57BL mice. Teratog. Carcinog. Mutagen. 7, 399-409.
33. Zamlauski-Tucker, M. J., and Cohen, J. J. (1987). Effect of substrate-free albumin on perfused rat kidney function. Renal Physiol 10, 360-362.